New report says US sanctions on Iran are killing cancer patients
Tehran (KNA) - The patient cancers in Iran are losing their lives as a result of US economic sanctions against the Islamic Republic, an Iranian pharmacology professor says.
In a Foreign Policy article, Dr. Abbas Kebriaee Zadeh, professor of toxicology and pharmacology at Tehran University of Medical Sciences, wrote that US sanctions against Iran indirectly hamper the flow of vital medicines for cancer patients in the Islamic Republic.
The article reveals that while Washington claims its harsh sanctions against Iran would not target the flow of medicine and other humanitarian necessities into Iran, banking sanctions are in fact increasing import prices, blocking supply chains, and creating deadly drug shortages in the country.
Citing the US Census Bureau, Kebriaee Zadeh adds that under the administration of US President Donald Trump during the last two years, the US’ annul exports of pharmaceutical products to Iran declined to an average of $8.6 million a year compared to $26 million annually during the Barack Obama-era sanctions.
Washington under Trump has also made it more difficult for European countries to export medicine to the Islamic Republic, Kebriaee Zadeh wrote.
“Swiss pharmaceutical exports to Iran fell 30 percent from 235 million Swiss francs ($240 million) in 2017 to 163 million francs ($167 million) last year, according to Swiss customs data. Even though sanctions were only fully reimposed in November 2018, Swiss exports that year fell below the 173 million francs ($178 million) annual average observed from 2008 to 2015,” he said.